Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection

Table 4 Correlation between preoperative fibrinogen-to-albumin ratio and clinicopathological characteristics in pancreatic ductal adenocarcinoma patients who underwent R0 resection, n (%)

Characteristic	Preoperative FAR		P value
	> 0.08, n = 126	≤ 0.08, n = 156
Age in yr			0.854
> 60	66 (23.4)	80 (28.4)
≤ 60	60 (21.3)	76 (27.0)
Sex			0.724
Male	66 (23.4)	85 (30.1)
Female	60 (21.3)	71 (25.2)
Clinical symptoms			0.001
Absent	14 (5.0)	43 (15.2)
Present	112 (39.7)	113 (40.1)
Diabetes			0.831
Absent	89 (31.6)	112 (39.7)
Present	37 (13.1)	44 (15.6)
Smoking status			0.765
Absent	95 (33.7)	120 (42.6)
Present	31 (11.0)	36 (12.8)
Alcohol consumption			0.335
Absent	108 (38.3)	127 (45.0)
Present	18 (6.4)	29 (10.3)
Family history of cancer			0.571
Absent	122 (43.3)	149 (52.8)
Present	4 (1.4)	7 (2.5)
Blood type			0.817
A	36 (12.8)	51 (18.1)
B	45 (16.0)	48 (17.0)
AB	10 (3.5)	12 (4.3)
O	35 (12.4)	45 (16.0)
Tumor location			< 0.001
Head and neck	77 (27.3)	53 (18.8)
Body and tail	49 (17.4)	103 (36.5)
Approaches of open surgery			< 0.001
Pancreaticoduodenectomy	77 (27.3)	53 (18.8)
Distal pancreatectomy with splenectomy	49 (17.4)	103 (36.5)
Degree of differentiation			0.208
Well	20 (7.1)	14 (5.0)
Moderately	93 (33.0)	124 (44.0)
Poorly	13 (4.6)	18 (6.4)
Lymphovascular invasion			0.729
Absent	92 (32.6)	111 (39.4)
Present	34 (12.1)	45 (16.0)
Perineural invasion			0.082
Absent	25 (8.9)	45 (16.0)
Present	101 (35.8)	111 (39.4)
Capsular invasion			0.360
Absent	19 (6.7)	30 (10.6)
Present	107 (37.9)	126 (44.7)
Maximum tumor diameter in cm			0.391
> 4	36 (12.8)	52 (18.4)
≤ 4	90 (31.9)	104 (36.9)
T stage			0.462
T1	13 (4.6)	21 (7.4)
T2	76 (27.0)	83 (29.4)
T3	37 (13.1)	52 (18.4)
Number of metastatic lymph nodes			0.988
Absent	72 (25.5)	89 (31.6)
Present	54 (19.1)	67 (23.8)
N stage			0.902
N0	72 (25.5)	89 (31.6)
N1	40 (14.2)	52 (18.4)
N2	14 (5.0)	15 (5.3)
TNM stage			0.494
IA	6 (2.1)	14 (5.0)
IB	40 (14.2)	52 (18.4)
IIA	26 (9.2)	23 (8.2)
IIB	40 (14.2)	52 (18.4)
III	14 (5.0)	15 (5.3)
Adjuvant therapy			0.531
Absent	58 (20.6)	66 (23.4)
Present	68 (24.1)	90 (31.9)
Preoperative CA19-9 level in U/mL			0.132
> 336.4	40 (14.2)	37 (13.1)
≤ 336.4	86 (30.5)	119 (42.2)
Preoperative plasma fibrinogen concentration in g/L			< 0.001
> 3.31	114 (40.4)	27 (9.6)
≤ 3.31	12 (4.3)	129 (45.7)
Preoperative plasma albumin level in g/L			< 0.001
> 45.2	15 (5.3)	70 (24.8)
≤ 45.2	111 (39.4)	86 (30.5)

FAR: Fibrinogen-to-albumin ratio; TNM: Tumor-Node-Metastasis.